Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

25.06 -0.27 (-1.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,957,827
Open 25.28
Bid (Size) 24.83 (2)
Ask (Size) 25.29 (2)
Prev. Close 25.33
Today's Range 24.92 - 25.39
52wk Range 13.40 - 25.88
Shares Outstanding 162,625,379
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Affordable Growth Stock with Fair Valuation and High Potential
ACADIA Pharmaceuticals (ACAD) offers strong growth, fair valuation, and solid financial health, making it a top pick for the Affordable Growth investment strategy. 
Via Chartmill
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Combines Strong Fundamentals with Bullish Technicals for Growth Potential
ACADIA Pharmaceuticals (ACAD) shows strong growth fundamentals with rising revenue, EPS, and solid margins, plus a bullish technical breakout, making it a promising stock pick. 
Via Chartmill

Performance

YTD
+34.3%
+34.3%
1 Month
+11.1%
+11.1%
3 Month
+14.0%
+14.0%
6 Month
+27.0%
+27.0%
1 Year
+59.0%
+59.0%

More News

Read More
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia (ACAD) Q2 Revenue Rises 9%
Via The Motley Fool
Topics Intellectual Property
Earnings Scheduled For August 6, 2025
Via Benzinga
The Analyst Verdict: ACADIA Pharmaceuticals In The Eyes Of 11 Experts
Via Benzinga
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Q2 2025 Earnings: Revenue Growth Meets Expectations, EPS Beats Estimates
Via Chartmill
Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer
From Acadia Pharmaceuticals Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A High-Growth Biotech Stock with Fair Valuation
Via Chartmill
What Analysts Are Saying About ACADIA Pharmaceuticals Stock
Via Benzinga
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Growth Stock with Technical Breakout Potential
Via Chartmill
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
Via Investor's Business Daily
Topics Intellectual Property
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Growth Stock at a Reasonable Valuation
Via Chartmill
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Growth Stock with Technical Breakout Potential
Via Chartmill
13 Analysts Assess ACADIA Pharmaceuticals: What You Need To Know
Via Benzinga
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Affordable Growth Stock
Via Chartmill
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent
From Acadia Pharmaceuticals Inc.
Via Business Wire
JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory
Via Benzinga
Topics Intellectual Property

Frequently Asked Questions

Is ACADIA Pharmaceuticals Inc. - Common Stock publicly traded?
Yes, ACADIA Pharmaceuticals Inc. - Common Stock is publicly traded.
What exchange does ACADIA Pharmaceuticals Inc. - Common Stock trade on?
ACADIA Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock?
The ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock is ACAD on the Nasdaq Stock Market
What is the current price of ACADIA Pharmaceuticals Inc. - Common Stock?
The current price of ACADIA Pharmaceuticals Inc. - Common Stock is 25.06
When was ACADIA Pharmaceuticals Inc. - Common Stock last traded?
The last trade of ACADIA Pharmaceuticals Inc. - Common Stock was at 08/18/25 04:00 PM ET
What is the market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock?
The market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock is 4.08B
How many shares of ACADIA Pharmaceuticals Inc. - Common Stock are outstanding?
ACADIA Pharmaceuticals Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.